survival estimates and Cox proportional hazards model adjusted for covariates were used for analyses.

**Results** The risks of recurrence of EOC increased steadily with increasing time from the start of primary treatment from 13.6% in 6-months to 71.0% after 12-months. In the final multivariate analyses, recurrence within 6 months of treatment was a significant independent predictor of poor OS in EOC patients (HR=7.23, 95%CI: 3.87–13.51, P<0.01).

**Conclusions** Our study suggests that recurrence within 6-months is an important prognostic factor that predicts poor OS in EOC. Early tumour recurrence may be a useful surrogate of overall survival and thus this information should be considered in the design of future tailored randomized controlled trials. Future strategies to improve OS in EOC patients should focus on identifying effective measures to prevent early tumour recurrence.

**EP290/#660** FIRST REPORT OF CLINICAL OUTCOMES WITH ESCALATED DOSES OF CISPLATIN AND DOXORUBICIN IN PIPAC FOR PERITONEAL CARCINOMATOSIS OF EPITHELIAL OVARIAN CANCER

1Sp Somashekar*, 1Rohit Kumar, 1Priya Kapoor, 2Susmita Rakshit, 1Aaron Fernandes, 1HK Karkik, 1Ashwin Rajagopal, 1Manipal Comprehensive Cancer Centre, Gynec and Surgical Oncology, Bangalore, India; 2Manipal Hospital, Oncopathology, Bangalore, India

**Methods** PIPAC was done at dose of cisplatin 15 mg/m2 and doxorubicin 3 mg/m2. The patient demographics, perioperative findings, adverse events, and outcomes were prospectively recorded. Response rate was graded as Peritoneal Regression Grading Score (PRGS). QoL of the patients was studied according to the EORTC QLQ – C30 score.

**Results** 18 PIPAC administrations were performed in 6 patients. The median hospital stay was 1.5 day (1–3 day). CTCAE grade 2 was observed in 3 patients, for abdominal pain and nausea, grade 3 fatigue in 2 patients. Transient increase in C-reactive protein was seen in 3 patients, hematological, renal and hepatic functions were not impaired in any patients except for mild transient elevation in AST and ALT levels in 3 patients. All patients completed 3 cycles of PIPAC. Of the 6 patients, 3 had complete response (PRGS 1) and remaining 2 had major (PRGS 2), 1 had minor response (PRGS 3). There was improvement in functional scale, symptom scale and overall global health status for all patients.

**Conclusions** PIPAC can be performed safely at doses of cisplatin 15 mg/m2 and doxorubicin 3 mg/m2. There is better objective & pathological response with this dose with no major complications or side effects to the patients. There is also improvement in quality of life. This dose should be new standard of care for further studies.

**EP291/#607** VALIDATION OF MULTI-GENE PANEL NEXT-GENERATION SEQUENCING FOR THE DETECTION OF BRCA MUTATION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED EPITHELIAL OVARIAN CANCER TISSUES

Eun Taeg Kim, Ha Eun Jeong, Hyung Joon Yoon, Ki Hyung Kim, Dong Soo Suh*. Pusan national university hospital, Obstetrics and Gynecology, Pusan, Korea, Republic of Korea

10.1136/ijgc-2022-igcs.382

**Objectives** The therapeutic effect of poly(ADP-ribose) polymerase inhibitors in patients with epithelial ovarian cancer (EOC) with somatic BRCA mutations is consistent with that observed in patients with germline BRCA mutations, indicating the importance of detecting both germline and somatic BRCA mutations concurrently. We compared the efficacy of multi-gene panel next generation sequencing (NGS) in EOC patients’ formalin-fixed, paraffin-embedded (FFPE) tissue to that of conventional Sanger sequencing in blood samples.

**Methods** This study included 48 patients with EOC, and both blood Sanger sequencing and FFPE tissue NGS were conducted in all of them. Clinical and pathological data were reviewed, including age at diagnosis, histology, and stage. Blood Sanger sequencing was performed using peripheral blood leukocytes. The target regions of 90 cancer-related genes were identified using FFPE tissue.

**Results** The median age of patients was 56.1 years, with serous carcinoma (n=40, 83.3%) and stage III (n=37, 77.1%) being the most common histology and International Federation of Gynecology and Obstetrics stage, respectively. FFPE tissue NGS identified ten pathogenic variants, including all eight pathogenetic variants identified by blood Sanger sequencing as well as two additional pathogenetic variants. In addition, FFPE tissue NGS identified 19 variants of uncertain significance (VUS), including all ten VUS identified by blood Sanger sequencing as well as nine additional VUS.

**Conclusions** The FFPE tissue multi-gene panel NGS had 100% sensitivity for detecting BRCA germline mutations and could detect additional somatic mutations. Furthermore, performing FFPE tissue multi-gene panel NGS followed by blood Sanger sequencing sequentially may help differentiate germline from somatic BRCA mutations for genetic counseling.

**EP292/#552** HOPE AND CHOICES: DIRECT PATIENT PREFERENCE ELICITION FOR DURABLE VERSUS FIXED SURVIVAL GAINS IN WOMEN WITH RECURRENT OVARIAN CANCER (ROC)

Charlotte Sun*, Amy Schneider, Sarah Huemerbecher, Shannon Westin, Larissa Meyer. The University of Texas, MD Anderson Cancer Center, Gynecologic Oncology and Reproductive Medicine, Houston, USA

10.1136/ijgc-2022-igcs.383

**Objectives** Hope in oncology can be defined as the desire to be a statistical outlier (tail of the curve). We examined preferences of ROC patients for tail of the curve survival.

**Methods** Patients chose between a clinical trial (chance at durable survival (DS)) and best supportive care (SC) or